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 Surgery for isolated tricuspid
regurgitation carries a high mortality risk,
especially in the setting of right
ventricular dysfunction and reoperation.
 Transcatheter valve therapy is as
promising alternative for treatment of
isolated tricuspid valve disease associated
with right heart failure.
 The NaviGate bioprosthesis is a novel
self-expanding valved stent designed to
treat functional tricuspid regurgitation.
 The preclinical evaluation shows that
transcatheter tricuspid valve implantation
using the NaviGate device is safe, is
feasible through 2 different approaches,
and results in a secure and stable
engagement of the native annulus, with
excellent hemodynamic and valve
performance.https://doi.org/10.1016/j.jacbts.2017.08.003
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ABBR EV I A T I ON S
AND ACRONYMS
ICE = intracardiac
echocardiography
PVL = paravalvular leak
RA = right atrium
RHF = right heart failure
RV = right ventricle/ventricular
RVOT = right ventricle outflow
TA = tricuspid annulus
TR = tricuspid regurgitation
TV = tricuspid valve
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68SUMMARYPatients with isolated functional or recurrent tricuspid regurgitation are often denied surgery because they are
considered to be at high risk. Transcatheter valve therapy provides a less invasive alternative for tricuspid
regurgitation associated with right heart failure. We have evaluated the feasibility of transcatheter tricuspid
valve implantation of the NaviGate valved stent in a long-term swine model. The valved stent was successfully
implanted through transjugular and transatrial approaches on the beating heart with excellent hemodynamic
and valve performance. No conduction disturbance or coronary obstruction was observed. This technology could
provide an alternative treatment for patients who are at high surgical risk with severe tricuspid regurgitation and
compromised right ventricular function. (J Am Coll Cardiol Basic Trans Science 2018;3:67–79) © 2018 The
Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).T ranscatheter valve technologies have beenemerging over the past decade as a new para-digm of heart valve treatment, especially in
selected high-risk patients whose care becomes
increasingly challenging; these technologies include
percutaneous replacement of aortic and pulmonic
valves, as well as multiple techniques regarding
repairing and replacing the mitral valve for functional
or degenerative mitral regurgitation. Secondary
tricuspid valve regurgitation (TR) is frequent in pa-
tients with long-standing left-sided valve disease,
particularly in the setting of severe pulmonary hyper-
tension and atrial fibrillation (1,2). Uncorrected,
moderate, or severe TR is associated with progressive
heart failure and premature death (3); even if
corrected, it is a marker of lower long-term survival.SEE PAGE 80However, the optimal timing and surgical technique
to eliminate TR remains undefined, showing that
tricuspid valve (TV) disease is not only underdiag-
nosed, but is also often surgically ignored. For many
years it was believed that secondary TRwould improve
after mitral valve surgery alone, and it was conse-
quently undertreated (4). Thus, for example, in 1967,
Braunwald et al. (5) recommended conservative
nonsurgical management of “functional” TR. In the
1980s, it was observed that patients who had under-
gone successful mitral surgery sometimes returned
years later with severe symptomatic TR and right heart
failure. When these patients underwent reoperation,
mortality was high (3). More recently, compelling
data have shown that surgically untreated secondary
TR can persist or even worsen despite correction of
the associated left-sided lesion (6), suggesting that
due to the severity and progressive course of the dis-
ease, an aggressive approach toward secondary TR is
warranted (7,8). Unfortunately, this approach is rarely
used, so patients usually do not undergo TVreoperations for secondary or recurrent TR, leading
to high mortality rates due to worsening right heart
failure (9).
In general, most of these patients present with renal
impairment, severe pulmonary hypertension, and
cardiac cirrhosis late in the disease state; given their
coagulopathic state and low likelihood of improvement
of right ventricular (RV) function in the perioperative
period, they become high-risk surgical candidates.
Thereby, transcatheter approaches to TV disease could
become an attractive alternative solution for these
patients who present a burgeoning clinical unmet
need for therapeutic advances. In addition, less
invasive strategies may allow for earlier surgical
treatment of TR, which may improve functional
capacity and reduce end-organ dysfunction.
The NaviGate bioprosthesis (NaviGate Cardiac
Structures Inc., Irvine, California) was designed
exclusively to overcome the technical challenges
associated with transcatheter valve implantation for
these high-risk patients. Herein, we describe the
preclinical feasibility study of a new transcatheter
self-expanding bioprosthetic TV, implanted in a
chronic porcine model using transcatheter and mini-
mally invasive approaches on a beating heart with a
sutureless valve implantation technique.
METHODS
NaviGate BIOPROSTHESIS. The NaviGate atrioven-
tricular valve is a biological valved stent; it consists of
a specifically configured Nitinol alloy stent into which
is mounted a trileaflet valvular mechanism fabricated
from equine pericardium that has been fixed in low
concentrations of buffered glutaraldehyde (Figures 1A
to 1D). The configuration of the stent is specifically
designed in a geometry that engages the tricuspid
annulus (TA) and TV leaflets from both inferior and
superior aspects and maintains a minimal extension
FIGURE 1 The NaviGate Valved-Stent
(A) Stent. (B) Inflow (left atrial) view. (C) Outflow (left ventricle) view. (D) Side view.
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 3 , N O . 1 , 2 0 1 8 Navia et al.
F E B R U A R Y 2 0 1 8 : 6 7 – 7 9 Transcatheter Tricuspid Valve Replacement
69into both the atrium and ventricle to avoid flow
dynamics alterations. Thus, the inferior aspect or
ventricular diameter is designed to match the dilated
tricuspid annulus typical of secondary TR, which has
a mean diametric dimension of 40  5 mm for most
patients. For this experimental study, the superior or
atrial size of the valve stent is maintained at 30 mm in
diameter, and the inferior or ventricular diameter at
40 mm, ensuring that transvalvular gradients will be
normal for a TV (DPmean #5 mm Hg) at normal flows.
This configuration results in a truncated conical
shape that helps to reduce the height of the valved
stent. This results in low intrusion into the right
atrium (RA) and RV, giving rise to a divergent nozzle
that, by slowing the flow entering the RV, reduces
energy loss and flow separation to optimize the
transvalvular gradient. From the surface of the trun-
coconal structures, specially configured structures
(winglets and graspers) are incorporated into theproximal (n ¼ 12) and distal (n ¼ 12) ends of the stent.
They are deployed sequentially at defined angles to
radially fix the bioprosthesis to the TA, minimizing
dislocation toward the adjacent chambers. The atrial
winglets of the NaviGate device are designed to be
relatively short and are covered by woven microfiber
polyester fabric lining to avoid compression of the
conduction fibers (Figure 1).
The preserved xenogeneic pericardial membrane is
used to fashion both leaflets and inner walls of the
valved stent. The lining of woven microfiber poly-
ester fabric supports the pericardial membrane wall
to protect its integrity and to prevent paravalvular
leakage (PVL). When totally assembled, the bio-
prosthesis proceeds through a proprietary dehydra-
tion process in which all glutaraldehyde and most of
its water are removed; it is then sterilized by ethylene
oxide exposure and stored in its primary container in
the dehydrated form until use.
FIGURE 2 Transatrial Tricuspid Valved Stent Delivery System
(A) Illustrated design of the transatrial delivery system. (B) Lateral view of the transatrial delivery system.
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70DELIVERY SYSTEM AND IMPLANTATION PROCEDURES.
Transatr ia l approach . The atrioventricular valved
stent is delivered transatrially through a minimally
invasive right thoracotomy directly through the free
wall of the RA into the TV, using a sutureless tech-
nique without cardiopulmonary bypass or rapid ven-
tricular pacing. The delivery device is depicted in
Figures 2A and 2B. It evokes the configuration of a
mitral commissurotomy device of decades past; when
introduced into the left atrium through a small inci-
sion, the curved shape and angulation of the shaft
leads the distal end into a central alignment position
in the TV. The valved stent is loaded and crimped
inside the distal capsule, and it can be retracted by
simple controlled turning of the proximal handle
knob. Retraction causes exposure of the ventricular
or distal aspect of the valved stent, causing the ven-
tricular winglets or graspers to deploy that may cap-
ture the leaflets above the tricuspid chordae
tendineae. The operator can readjust the depth and
angle of the valve/delivery system using fluoroscopy
and intracardiac echocardiography (ICE) to achieve a
good relationship between the RV, RA, and the plane
of the TV annulus for final deployment.
Details of the delivery systems and surgical trans-
atrial implantation technique of the valve are pre-
sented in Supplemental Appendix 1.
Trans jugular approach . The transjugular delivery
system consists of an 80-cm usable catheter with a
central conduit accommodating a 0.038-inch guide-
wire and a 24-F shaft reinforced with interior metallic
coiling, for the most part, to optimize its tracking
through the vasculature and imaging visibility. Thedistal section is flexible, as that includes the 30-F
outer diameter stent-enclosing capsule and a mech-
anism that allows steering in 2 directions, including
depth control by forward or reverse motion of the
distal capsule when in the immediate vicinity of the
TV annular plane. The introducer sheath (w45 cm and
45-F outer diameter) has a hydrophilic coating for
atraumatic insertion into the vessel. The catheter is
pictured in Figures 3A and 3B. After gaining access
into the RA through the right jugular with a modified
Seldinger technique (viewed both by fluoroscopy and
ICE), the distal end of the delivery system was posi-
tioned coaxially to the center of the swine TV, and the
tricuspid valved stent was aligned with the plane of
the TA. The middle annular region of the tricuspid
valved stent was visible by fluoroscopy, with the
distal anchors or grasper tips in the contracted or
crimped state within the distal capsule. Details of the
percutaneously implanted valve are presented in
Supplemental Appendix 1.
EXPERIMENTAL DESIGN. In v ivo assessment of
safety . These studies were designed both to assess
the safety of the NaviGate device and to obtain a
partial assessment of its effectiveness in performing
the designed function; the latter assessment aimed to
provide sufficient safety data for the first-in-human
evaluation.
Long-term in v ivo study . A bioprosthesis valve
replacement is intended to remain in situ for its life or
the life of the patient. Thus, long-term implantation
in the in vivo model was studied to preliminarily
assess the continuous function and durability of the
FIGURE 3 Transjugular Tricuspid Valved Stent Delivery System
(A) The delivery system distal capsule extended. (B) The delivery system distal capsule articulated 90.
TABLE 1 Model Information for Transjugular Implant in a
Long-Term Animal Study
Animal model Swine, 85–90 kg
Access site for
transjugular
Percutaneous right jugular vein access—
sutureless implantation technique
without cardiopulmonary bypass
Delivery system Size 30-F outer diameter
Devices NaviGate valved-stent, 30-mm inflow and
40-mm outflow, 12 tines in inflow and
outflow
Implantation interval Chronic long term ($25 days)
Number of animals 6 transjugular
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 3 , N O . 1 , 2 0 1 8 Navia et al.
F E B R U A R Y 2 0 1 8 : 6 7 – 7 9 Transcatheter Tricuspid Valve Replacement
71device. In the absence of a natural, practical, and
cost-effective animal model of tricuspid regurgitation
(TR), the healthy swine was chosen to test the safety
of the device. Safety includes the proper delivery and
deployment of the device with the delivery system.
The effectiveness focused on assessment of the per-
formance of the valved stent and its durability.
Accordingly, complete percutaneous, transjugular
access, catheter-guided implantation of a NaviGate
self-expanding bioprosthesis into the native TV of
healthy swine was successfully performed (n ¼ 6; 85
to 90 kg) (Table 1).
Previously a series of 6 NaviGate tricuspid valved
stents were implanted in 6 healthy swine (n ¼ 6; 95 to
105 kg) in the TV orthotopic position for a long-term
preclinical study using a minimally invasive right
thoracotomy approach on a beating heart with a
sutureless implantation technique (Table 2). All valve
prostheses used in this study have equivalent design
and fabrication methods, and they were evaluated in
a pulsatile mock circulatory loop for hemodynamic
performance and quality control. The long-term
study also assesses the replicability of both implan-
tation approaches, the valved stent’s suitability tomaintain valve function and valve hemodynamic
function, durability, right ventricular outflow tract
(RVOT) obstruction and coronary arteries obstruction
if any, the formation of interfering pannus, proce-
dural success and blood loss, possible calcification of
biological tissue, and absence of thrombosis.
IMPLANTATION PROCEDURE. Pre-operative management.
All animals received humane care in compliance
with the Animal Welfare Act and Public Health
Services policies, and the study protocol was
approved by the Institutional Animal Care and Use
TABLE 2 Model Information for Transatrial Implant in a
Long-Term Animal Study
Animal model Swine, 95–105 kg
Access site for transatrial Through a mini-thoracotomy RA access—
sutureless implantation technique
without cardiopulmonary bypass
Delivery system Size 30-F outer diameter
Devices NaviGate valved-stent, 30-mm inflow
and 4-mm outflow, 12 tines in inflow
and outflow
Implantation interval Chronic long term ($25 days)
Number of animals 6 transatrial
FIGURE 4 Fluoros
(A) Positioning of th
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72Committee at the Gateway Innovation Laboratory,
Shanghai, China.
The details for each of the modes of approach
and anesthesia management are given in
Supplemental Appendix 1. In brief, after gaining ac-
cess into the RA (viewed both by fluoroscopy and ICE)
through the antegrade transatrial and transjugular
approach, the distal end of the delivery system was
positioned coaxially with the center of the swine TV,
and the tricuspid valved stent aligned with the plane
of the TA. The middle annular region of the tricuspid
valved stent is visible by fluoroscopy, with the distal
anchors or grasper tips in the contracted or crimped
state within the distal capsule. The tricuspid annular
plane was defined using fluoroscopic imaging of
guidewires in both the right coronary artery and
left circumflex artery. Coaxiality of the stented
valve to the tricuspid annulus was confirmed
prior to deployment using multimodality imaging;
fluoroscopic identification of the tricuspid annulus
was defined by the guidewire, and positioning in the
center of the annulus plane was guided by ICE.copy: Transatrial Tricuspid Valved Stent Implant
e valved stent in the tricuspid annulus plane. (B) Slow release of the valvedWhen the operator, guided by imaging, was confi-
dent that the valved stent was coaxial in the right
landing zone and ready to deploy, further turning of
the proximal knob slowly retracted the capsule,
allowing the expansion of the valved stent’s distal
perimeter to reach close to 80% of the nominal
diameter. Then, the ventricular winglets or distal
graspers engaged the TV leaflets. The final release
was achieved with a turn of the proximal knob, that
allowed the atrial anchors to deploy, and the tricuspid
valved stent was delivered into its proper locus,
anchored from the ventricular as well as from the
atrial aspects of the native TV (Figure 4). No rapid
pacing was required during this operation as the de-
vice functions during a slow controlled release when
it reaches 60% of its opening diameter. Thus, there
was no obstruction of the blood flow or hemodynamic
compromise. Details of the percutaneously and sur-
gically implanted valve are presented in
Supplemental Appendix 1.
POST-DEPLOYMENT MEASUREMENTS AND MANAGEMENT.
RV angiography was performed to confirm proper
placement of the valve and to rule out RVOT
obstruction and/or TR (central to paravalvular regur-
gitation based on echocardiography guidelines [10]),
and a coronary artery angiogram was performed to
rule out coronary artery obstruction or compression.
Both transesophageal echocardiogram and ICE were
used to confirm placement and proper valve function.
Echocardiography, hemodynamic interrogations, and
valve function assessment were repeated after 20 min
when hemodynamic stability was achieved. When
hemostasis was ensured, chest, neck, and femoralstent. (C) Full implantation in the tricuspid annulus.
FIGURE 5 Echocardiography: Transatrial Tricuspid Valved Stent Implantation
(A and B) Echocardiographic short-axis view. (C and D) Echocardiographic long-axis view.
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73incisions were closed in layers in the usual fashion.
The animals recovered in the acute care unit after the
procedure. All animals were followed clinically for
manifestation of heart failure and with serial echo-
cardiogram assessment. All animals underwent post-
mortem examination of the device and cardiac
tissues. Echocardiographic assessment was per-
formed in all animals before euthanasia as well as at
3 and 6 months for live animals. Details of the
post-implant measurements and management are
presented in Supplemental Appendix 2.
DATA ANALYSIS. Hemodynamic measurements after
NaviGate stented valve implantation were summa-
rized using standard descriptive statistics and are
reported as mean  SD. Analysis of data was per-
formed using a paired Student t test with 2-sided
comparisons. A p value of 0.05 was considered to
indicate statistical significance. Data analysis was
performed using a statistical software package (SPSS
for Windows, version 15.0, IBM, Armonk, New York).RESULTS
LONG-TERM STUDY: TRANSATRIAL ACCESS. Long-
term transcatheter RA access of an orthotopic
tricuspid valve implantation was performed in the
swine model (n ¼ 6; 95 to 105 kg) ($25 post-operative
days). All valves were successfully implanted with no
technical difficulties during prostheses deployment,
providing a 100% procedural success. Although the
deployment was feasible for the novel valved stent,
the use of a well-known minimally invasive RA access
under direct vision with a sutureless implantation
technique provided an advantage. The follow-up
varied from 1 to $25 days per protocol. All animals
but 1 survived the intervention: 1 died during the
procedure after developing acute severe TR second-
ary to annulus-prosthesis mismatch that resulted in
prosthesis RV migration. Of the remaining 5 animals,
1 animal survived 30 days and was sacrificed per
protocol; 2 animals survived 150 days and were
FIGURE 6 Fluoros
(A and B) Fluorosco
TABLE 3 Chronic Long-Term Tricuspid Valve Study
Sex, Body
Weight (kg) Model #
Ice C-C
Dimension (cm)
Blood
Loss (ml)
Time for
Implant (min)
DPp mm Hg
(peak)
DPm mm Hg
(mean)
RVOT
Velocity (m/s)
RVOT Gradient
(mean/mm Hg)
Leakage
Central or
Paravalvular
Duration
(days)
F, 105 TA X27 3.59 250 6.0 6.2 4.0 0.49 1.1 Mild central 30
F, 104 TA X27 3.93 400 12 6.0 2.5 0.47 1.2 No 150
M, 98 TA X27 3.93 300 5.0 4.0 2.0 0.45 1.8 No 150
F, 100 TA X27 3.92 350 7.0 5.4 1.7 0.48 0.9 No $150/alive
F, 96 TA X27 4.55 1,000 EUTH EUTH — — — TVD 0.3
F, 95 TA X27 4.42 150 6.0 5.0 3.1 0.35 1.5 No $150/alive
M, 85 TJ X27 4.00 50 15 6.0 2.8 0.50 2.0 Mild PVL 210
M, 88 TJ X27 3.70 100 12 5.4 2.0 0.41 1.8 No 210
F, 90 TJ X27 4.12 50 17 6.4 3.2 0.52 1.6 No $120/alive
F, 85 TJ X27 3.93 75 18 4.8 2.5 0.44 2.1 Mod PVL $120/alive
M, 89 TJ X27 4.10 85 15 5.0 2.7 0.53 2.2 No $90/alive
M, 90 TJ X27 3.88 90 13 4.7 2.2 0.49 1.9 No $90/alive
C-C ¼ commissure-to-commissure; EUTH ¼ euthanasia; ICE ¼ intra-cardiac echocardiography; Pm mmHg ¼ mean pressure gradient across the valved stent; Pp mmHg ¼ peak pressure gradient across the
valved stent; PVL ¼ paravalvular leak; RVOT ¼ right ventricular outflow tract; TA ¼ transatrial; TJ ¼ transjugular; TVD ¼ total valve dislodgement.
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74sacrificed per protocol; and 2 animals are still alive.
No animals that survived the procedure died sec-
ondary to a cardiac or noncardiac complication.
Echocardiographic and fluoroscopic assessment
confirmed excellent function of the new TV in
all animals, with accurate alignment and secure
anchoring of the valved stent onto the TA (Figures 4
and 5). Conformance to the tricuspid annulus with
no PVL or central TR was observed in 4 valves, with 1
mild PVL and 1 central severe TR/valve dislodgment.
In all cases of successful implantation (n ¼ 5) of the
new valve, there was a clear unobstructed RVOT, no
pericardial effusion, normal coronary artery anatomy,
and no arrhythmias, with a preservation of the sub-
valvular apparatus. Valve function evidenced normalcopy: Transjagular Tricuspid Valved Stent Implantation
py: transjugular tricuspid valved stent. (C) Right ventricle angiogram.hemodynamic performance and normal pressure
gradient across the implanted valve (#3 mm Hg), as
well as RVOT gradients (Table 3). All animals had
normal RV function before the procedure and pre-
served RV function during follow-up period and at
the time of euthanasia.
The entire procedure time in all study animals
ranged from 40 to 55 min, the time from the mini-
mally invasive right thoracotomy to position the de-
livery system at the TV annulus after surgical access
ranged from 6 to 9 min, and the NaviGate bio-
prosthesis deployment time ranged from 1 to 3 min.
LONG-TERM STUDY: TRANSJUGULAR ACCESS. Long-
term transcatheter right jugular access of an
FIGURE 7 Echocardiography: Transjagular Tricuspid Valved Stent Implantation
(A and B) Echocardiographic short-axis view. (C and D) Echocardiographic long-axis view.
FIGURE 8 Pathology
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75orthotopic tricuspid valve implantation was per-
formed in a swine model (n ¼ 6; 85 to 90 kg) ($25
post-operative days). All valves were successfully
implanted with a complete percutaneous approach,
with no technical difficulties during prostheses
deployment, providing a 100% procedural success.
The delivery system’s articulation feature up to 90
certainly provides an elegant mechanism to align the
new valve in the center of the TA and, when com-
bined with the guidewires’ position inside of the right
and circumflex coronary arteries that provides a
fluoroscopic image of a horizontal plane of the TA,
helps the operator secure a safe and accurate landing
zone to deploy the valve on a beating heart with a
sutureless implantation technique.
All 6 animals survived the intervention: 2 animals
survived >210 days, 2 animals survived >120 days and
are still alive, and another 2 animals survived>90 days
and are both still alive. No animals that survived the
procedure died secondary to cardiac or noncardiac
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76complication. Echocardiographic and fluoroscopic
assessment confirmed excellent function of the new
TV in all animals, with accurate alignment and secure
anchoring of the valved stent onto the TA (Figures 6
and 7). Conformance to the tricuspid annulus with no
PVL or central TR was observed in 4 valves, whereas 1
animal hasmild PVL and 1 animal hasmoderate PVL. In
all 6 animals, the new NaviGate valve left a clear, un-
obstructed RVOT, no pericardial effusion, normal
coronary artery anatomy, and no arrhythmias or atrial
ventricular conduction disturbances, with a preser-
vation of the subvalvular apparatus.
Valve function evidenced normal hemodynamic
performance and normal pressure gradient across the
implanted valve (#4 mm Hg), as well as RVOT gradi-
ents (Table 3). All animals had normal RV function
before the procedure and preserved RV function dur-
ing the follow-up period and at the time of euthanasia.
The entire implantation procedure time in the
study ranged from 45 to 60 min, the time from the
percutaneous right jugular access to position the de-
livery system at the TV annulus ranged from 12 to
15 min, and the NaviGate bioprosthesis deployment
time ranged from 1 to 3 min.
There was no significant difference between the
peak gradient across the valved stent in both ap-
proaches, transatrial versus transjugular (p ¼ 0.9),
indicating feasibility for device implantation using the
2 approaches.
EUTHANASIA, GROSS NECROPSY, AND PATHOLOGY.
After sacrificing the 3 animals per protocol and 1 animal
that died in the operating room, a thorough autopsy
was performed according to the Gateway’s detailed
protocols for autopsy and pathology, focusing on the
biocompatibility of the devices. The heart was excised
and weighed. A cursory view of the morphology at
necropsy focused on reviewing the placement of the
valved stent and its structure and assessment of signs
of device-related trauma. A gross examination showed
a proper anchoring and alignment of the valve in all
animals except 1, which had a total valve dislodgment
due to extreme tricuspid annulus to prosthesis
mismatch. There were no signs of wear or damage to
the anchoring winglets. Assessment of the chronic
tissue response to the valve and anchoringmechanism
valve struts and leaflets was also of particular interest;
there was a normal response and normal evidence of
tissue ingrowth, without thrombus formation. There
was a complete circumferential seal in both sides of the
stented valve without evidence of device-related
trauma (Figure 8). Both the stent and valve leaflets
were intact in all animals with no signs of damage.
A Faxitron x-ray cell was used to visualize the po-
sition of the valved stent within the tricuspidapparatus in the resected rinsed heart, which identi-
fied no distortion or fracture of any of the segments or
stent elements in the long-term study.
DISCUSSION
Tricuspid valve disease continues to present a chal-
lenging problem to cardiovascular specialists, espe-
cially in patients who develop TR associated with RV
dysfunction and right heart failure (RHF) (11,12).
Recently, a more aggressive approach has been pro-
moted for treatment of functional TR during left heart
valve surgery to avoid high-risk reintervention
thereafter (13–15). Patients who present for isolated
TV surgery are at high risk of mortality, especially
with RV dysfunction and reoperation (16–18). This
could be attributed to RHF phenomena in the setting
of long-standing TR that includes systemic venous
congestion, volume overload, renal dysfunction, liver
congestion, hypersplenism, and severe coagulopathy.
Hence, many of these patients have been denied
traditional open-heart surgical therapy, although the
operation per se is technically less demanding than
other valve surgeries.
In light of the former clinical challenges, and along
with recent advances in percutaneous valve implan-
tation techniques, the transcatheter approach stands
out as a promising alternative for treatment of iso-
lated TV disease associated with RHF. Several trans-
catheter techniques have been experimentally
developed and tested in animal models, but few have
been clinically applied in humans for treatment of TR
(19): 1) transcatheter valve implantation at the vena
cava level to prevent backflow of TR and decrease
systemic congestion (Sapien [Edwards Lifesciences,
Irvine, California] and Tric Valve [P & F Products &
Features Vertriebs GmbH, Weßling, Germany]); 2)
devices applied to reduce tricuspid annulus diameter
(Mitralign [Mitralgin Inc., Tewksbury, Massachusetts]
and TriCinch [4Tech Cardio, Galway, Ireland] de-
vices); 3) devices applied to decrease TR volume and
improve leaflet coaptation (FORMA device [Edwards
Lifesciences]); 4) the Mitraclip device (Abbott
Vascular, Santa Clara, California) used for edge-to-
edge repair of TR; and 5) the transatrial intra-
pericardial tricuspid annuloplasty (TRAIPTA,
National Institute of Health, Bethesda, Maryland)
device (19). Regarding malfunctioning TV bio-
prosthesis, few groups have reported successful
transcatheter valve-in-valve implantation (20,21).
All new transcatheter techniques were limited to a
small number of patients who were at prohibitive risk
for surgical intervention in a trial to improve their
clinical symptoms and to test feasibility. Particular
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77concerns were raised for transcatheter caval devices
that include persistent right heart volume overload,
RV failure, and atrial arrhythmia; however, these
concerns were not evidenced on early results (22,23).
The overall early and midterm outcomes showed
transcatheter treatment of isolated TV disease to be
feasible and promising, yet long-term follow-up as
well as prospective trials are required to better
evaluate the efficiency and durability of these new
techniques. However, there are no reports of trans-
catheter valve implantation at the native tricuspid
annulus level in humans.
In comparison to the evolving transcatheter aortic
valve implantation, the TV anatomic features render
transcatheter therapy more challenging. Obstacles for
percutaneous repair approaches to the TV include the
lack of stable adjacent structures for device place-
ment, such as dilated annulus with its complex
morphology of the TV; the dynamic geometry of the
tricuspid annulus; and the absence of calcification.
Furthermore, the close proximity of the coronary si-
nus ostium, atrioventricular node, and inferior vena
cava to the TV result in many more technical diffi-
culties for successfully deploying percutaneous
repair devices. However, technology continues to
advance, and newer techniques are being developed
and tested in the preclinical setting to overcome
these challenges before application in humans.
Bai et al. (24) described transcatheter implantation
of a porcine pericardial valve in the tricuspid position
in 10 healthy sheep under fluoroscopic guidance. Two
deaths occurred periprocedurally related to cardiac
arrhythmias. No significant TR developed in any an-
imals during the follow-up period (24). Boudjemline
et al. (25) have reported successful insertion of a
novel percutaneous TV. Complications that were re-
ported in this study include entrapment of the device
in tricuspid chordae, leading to its incomplete valve
opening, and a significant PVL in a separate animal.
This device has not yet advanced to human studies
(25). We developed a novel bioprosthesis that fulfilled
all criteria required for successful transcatheter TV
replacement without cardiopulmonary bypass using
2 different access approaches. Feasibility of the
NaviGate prosthesis was tested in long-term pre-
clinical models with overall satisfactory results.
Echocardiography showed no significant post-
implantation TR or high transvalvular gradients.
There was no obstruction of RVOT, coronary arteries,
or subvalvular apparatus. The valve anchoring was
facilitated by a combination of 3 principles: a gentle
radial force of the stent over the TA, a truncated cone
or frustum configuration design that uses the RVpressure in systole to maintain the stented valve in
proper position, and ventricular winglets that engage
the tricuspid annulus, together creating a strong
valvular seal.
Small atrial winglets covered with a lining of woven
microfiber polyester fabric allow for a low intrusion of
the valved stent into the RA; protect the integrity of
anatomic structures, such as coronary sinus and
conduction bundle; and also prevent PVL, minimizing
dislocation toward the adjacent chambers. At this
time, the NaviGate device has been implanted in 3
patients in the tricuspid position with no conduction
disturbance complications (26).
STUDY LIMITATIONS. An important limitation is the
use of healthy animal models, because the TV is not
enlarged with a very small atrial cavity that precludes
substantial extension of the bioprosthesis and easy
navigation inside the RA. The healthy pig differs
widely from the patient presenting with moderate
or severe tricuspid incompetence. Specifically, in
humans with long-standing TR resulting from
annular dilatation, the tricuspid annulus is >40 mm
in diameter in many cases, which is very different
from the model used in our study.
Achieving a good measurement of the TA as well as
good visualization during valve deployment is critical
to avoid mismatch of the TV prosthesis to the native
TA; we experienced a total valve migration because of
inappropriate TA measurements with intracardiac
and transesophageal echocardiogram. That is why
imaging technologies such as computerized tomog-
raphy and 3-dimensional echocardiography are
extremely important to provide more accurate guid-
ance when performing transcatheter valve implanta-
tion in humans. However, using these imaging
technologies would be challenging in our study, as
they are not found in animal laboratories as a rule.
The valved stent could not be completely retrieved
once released, so to avoid paravalvular leak in the
presence of a larger tricuspid annulus, the size of the
valved stent should be larger for pathological TR.
CONCLUSIONS
Tricuspid valve disease continues to present a chal-
lenging problem to cardiovascular specialists, espe-
cially in patients who develop tricuspid insufficiency
associated with left heart valve disease or severe RV
dysfunction. Because reoperation for recurrent TR
carries high mortality rates and recurrence of TR after
surgical repair is common, few patients are offered
reoperation. Percutaneous approaches to TV disease
could be an attractive alternative solution. In
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Transcatheter valve therapy has been progressively
evolving to provide alternative options for high-risk
surgical patients. In this work, we have tested the
feasibility of the NaviGate valved stent in an animal
model in preparation for clinical application. Two
delivery approaches are of particular value for
high-risk patients with recurrent TR after prior cardiac
surgery. Different sizes of the NaviGate valved stent
are available to treat functional TR with dilated
annulus and for implantation in a previously placed
annuloplasty ring.
TRANSLATIONAL OUTLOOK: At this time, the
NaviGate valved stent has been successfully
implanted in 2 patients who are at prohibitive surgical
risk with severe TR. The short-term results suggest
that the procedure is safe and feasible. Further
development of the current device and delivery
system is ongoing to achieve optimal clinical results.
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78addition, the less invasive strategies may allow for
earlier TR intervention than is currently practiced.
There are many challenges and obstacles to emerging
percutaneous approaches; however, with the
advancement of cardiac imaging and percutaneous
devices, development in this area is likely to
continue.
This preclinical evaluation shows that trans-
catheter NaviGate TV orthotopic implantation in a
chronic porcine model is feasible and safe and results
in a secure and stable engagement of the native
annulus with excellent hemodynamics and valve
performance. This new device offers both percuta-
neous and minimally invasive implantation tech-
nique options without the need of cardiopulmonary
bypass, which may be a potential effective alternative
treatment for high-risk patients who are unsuitable
for traditional cardiac surgery with severe TR and
compromised RV function.
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